

TABLE 2. Anti-inflammatory agents that failed to provide significant cardiovascular risk reduction

Target	Agent	Trial	Number of participants
Oxidized LDL	Succinobulol	ARISE	6144
sPLA2	Verespladib	VISTA-16	5000
LpPLA2	Darapladib	STABILITY	15,000
LpPLA2	Darapladib	SOLID-TIMI 52	13,000
P-selectin	Inclacumab	SELECT-ACS	544
P-selectin	Inclacumab	SELECT-CABG	380
IL-1RI	Anakinra	IL-HEART	182
5-LO	Atreleuton	NCT00358826	191
p38 MAPK	Losmapimod	LATITUDE-TIMI	3,503
Dihydrofolatereductaseinhibitor	Methotrexate	CIRT	4,786

Abbreviations: sPLA2: secretory phospholipase A2, LpPLA2: lipoprotein-associated phospholipase A2, interleukin 1RI: IL-1RI, interleukin 1A: IL-1A, 5-LO: 5-lipoxygenase, MAPK: mitogen-activated protein kinase, ARISE: Aggressive Reduction of Inflammation Stops Events trial, VISTA-16: Vascular Inflammation Suppression to Treat Acute Coronary Syndrome, STABILITY: STabilization of Atherosclerotic plaque By Initiation of darapLadIbTherapY trial, SOLID-TIMI 52: Stabilization Of pLaquesusIngDarapladib-Thrombolysis In Myocardial Infarction 52 trial, SELECT-ACS: P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non-ST-Segment Elevation Myocardial Infarction trial, SELECT-CABG: Effects of P-Selectin Antagonist Inclacumab in Patients Undergoing Coronary Artery Bypass Graft Surgery trial, LATITUDE-TIMI: Losmapimod to Inhibit p38 MAP Kinase as a Therapeutic Target and Modify Outcomes After an Acute Coronary Syndrome trial, CIRT: Cardiovascular Inflammation Reduction Trial